Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma
Recruiting · NCT05726383 · Registry updated 2026-05-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma | Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone disorder, musculoskeletal system disorder, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-05-22 | NCT05726383 |
5 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hackensack Meridian Health | 52 |
| Iscador AG, Arlesheim, Switzerland. | 1 |
| M.D. Anderson Cancer Center | 1145 |
| Susan Zabransky Hughes Foundation | 1 |
| Tackle Kids Cancer | 1 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hackensack University Medical Center | Hackensack | United States | 308 |
| M.D. Anderson Children's Cancer Hospital | Houston | United States | 1 |